EAU 2013 - Programme Book - YouMed

Sunday, 17 March - EAU Programme
Abstract Session
15.45 - 17.15 New and old minimally invasive BPH therapies
Silver Hall - Level N2
Poster Session 52
Chairs: S. Madersbacher, Vienna (AT)
K.M.L. Van Renterghem, Hasselt (BE)
Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes
in length, followed by 2 minutes for discussion.
626 NX-1207 for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia (BPH)
N.D. Shore, R.F. Tutrone Jr. (Myrtle Beach, South Carolina, Baltimore, Maryland, United States of America)
627 Effect of onabotulinum toxin type A intraprostatic injection on the outcome of BPH patients refractory to
medical therapy: A 2-year study
T. Gorgal Rodrigues De Carvalho, J. Silva, R. Pinto, P. Dinis, F. Cruz (Porto, Portugal)
628 Clinical outcome of prostatic arterial embolization for patients with benign prostatic hyperplasia and
moderate to severe lower urinary tract symptoms – 365 cases
L. Campos Pinheiro, J. Pisco, H. Rio Tinto, T. Bilhim, L. Fernandes, M. Duarte, J. Preira, A. Gouveia Oliveira
(Lisbon, Portugal)
629 The Prostatic Urethral Lift (PUL), a minimal-invasive transurethrally-placed implant, proves its efficacy in
the treatment of LUTS in patients with BPH in daily clinic practice outside of studies
F. Miller, M. Schönthaler, R. Berges, C. Gratzke, B. Amend, J. Bedke, S. Kruck, J. Zumbé, U. Wetterauer,
C. Stief, A. Stenzl, K-D. Sievert (Tübingen, Freiburg, Cologne, Munich, Leverkusen, Germany)
630 The MediTate® temporary implantable nitinol device (TIND) proves safe and effective in relieving bladder
outlet obstruction related to benign prostatic hyperplasia
F. Porpiglia, D. Amparore, C. Fiori (Orbassano (Turin), Italy)
631 Transurethral water vapor therapy for BPH; initial clinical results of the first in man trial and Rezūm I
pilot study
C. Dixon, E. Rijo Cedano, D. Pacik, V. Vit, G. Varga, L. Mynderse, D. Hanson, T. Larson (New York, Rochester,
United States of America; La Romana, Dominican Republic; Brno, Czech Republic)
632 The factors associated with occurrence and recovery of transient urinary incontinence after holmium laser
enucleation of the prostate
J-Y. Han, S-W. Park, L. Sang Don, M.K. Chung (Yangsan, South Korea)
633 Evaluating the efficacy and impact on quality of life of 120 Watts KTP LASER for treating bladder outlet
obstruction
D. Kaushal (Taree, Australia)
634 Photoselective vaporisation of the prostate using the 180W lithium triborate laser in the treatment of
benign prostatic obstruction: An international multicenter experience
A.S. Chung, A. Bachmann, E. Collins, F. Gomez Sancha, S. Tabatabaei, H.H. Woo (Sydney, Australia; Basel,
Switzerland; San Francisco, Boston, United States of America; Madrid, Spain)
635 Significant absorption of irrigation fluid is frequently detectable during high-power Greenlight laser
vaporization of the prostate: Results from a prospective investigation using the expired breath ethanol test
M.S. Wettstein, N. Grossmann, C.D. Fankhauser, L.J. Hefermehl, J.C. Capol, M. Zimmermann, T. Sulser,
A. Müller, T. Hermanns (Zürich, Switzerland)
EAU Milan 2013
221
Sunday